Simply Wall St.
Health Canada LIVMARLI Decision And Bluejay Deal Shape Mirum Outlook
📈
AI Sentiment
Highly Positive
9/10
- Home
- MIRM
as of 02-11-2026 3:45pm EST
$100.78
$0.13
-0.13%
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 4.2B | IPO Year: | 2019 |
| Target Price: | $102.64 | AVG Volume (30 days): | 733.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.88 - $105.74 | Next Earning Date: | 02-26-2026 |
| Revenue: | $471,794,000 | Revenue Growth: | 53.66% |
| Revenue Growth (this year): | 55.91% | Revenue Growth (next year): | 23.97% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | 44.3M | FCF Growth: | N/A |
AI-Powered MIRM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 71.52%
71.52%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Mirum Pharmaceuticals Inc. (MIRM)
Radovich Peter
Sell
PRESIDENT AND COO
MIRM Feb 2, 2026
Avg Cost/Share
$103.30
Shares
2,631
Total Value
$271,791.51
Owned After
20,655
SEC Form 4
Peetz Christopher
Sell
CHIEF EXECUTIVE OFFICER
MIRM Feb 2, 2026
Avg Cost/Share
$103.30
Shares
9,108
Total Value
$940,888.28
Owned After
160,294
SEC Form 4
Howe Jolanda
Sell
SVP, GLOBAL CONTROLLER
MIRM Feb 2, 2026
Avg Cost/Share
$103.30
Shares
968
Total Value
$99,997.79
Owned After
4,503
SEC Form 4
BJERKHOLT ERIC
Sell
CHIEF FINANCIAL OFFICER
MIRM Jan 26, 2026
Avg Cost/Share
$96.19
Shares
1,053
Total Value
$101,290.18
Owned After
43,741
SEC Form 4
Radovich Peter
Sell
PRESIDENT AND COO
MIRM Jan 26, 2026
Avg Cost/Share
$96.19
Shares
3,143
Total Value
$302,331.46
Owned After
20,655
SEC Form 4
Peetz Christopher
Sell
CHIEF EXECUTIVE OFFICER
MIRM Jan 26, 2026
Avg Cost/Share
$96.19
Shares
6,831
Total Value
$657,087.55
Owned After
160,294
SEC Form 4
Howe Jolanda
Sell
SVP, GLOBAL CONTROLLER
MIRM Jan 26, 2026
Avg Cost/Share
$96.19
Shares
842
Total Value
$80,993.66
Owned After
4,503
SEC Form 4
Heron Patrick J
Buy
Director
MIRM Jan 23, 2026
Avg Cost/Share
$68.48
Shares
131,425
Total Value
$8,999,984.00
Owned After
459,010
SEC Form 4
BJERKHOLT ERIC
Sell
CHIEF FINANCIAL OFFICER
MIRM Jan 22, 2026
Avg Cost/Share
$93.33
Shares
1,421
Total Value
$132,615.11
Owned After
43,741
SEC Form 4
Radovich Peter
Sell
PRESIDENT AND COO
MIRM Jan 22, 2026
Avg Cost/Share
$93.33
Shares
2,382
Total Value
$222,300.63
Owned After
20,655
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Radovich Peter | MIRM | PRESIDENT AND COO | Feb 2, 2026 | Sell | $103.30 | 2,631 | $271,791.51 | 20,655 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Feb 2, 2026 | Sell | $103.30 | 9,108 | $940,888.28 | 160,294 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Feb 2, 2026 | Sell | $103.30 | 968 | $99,997.79 | 4,503 | |
| BJERKHOLT ERIC | MIRM | CHIEF FINANCIAL OFFICER | Jan 26, 2026 | Sell | $96.19 | 1,053 | $101,290.18 | 43,741 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Jan 26, 2026 | Sell | $96.19 | 3,143 | $302,331.46 | 20,655 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Jan 26, 2026 | Sell | $96.19 | 6,831 | $657,087.55 | 160,294 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Jan 26, 2026 | Sell | $96.19 | 842 | $80,993.66 | 4,503 | |
| Heron Patrick J | MIRM | Director | Jan 23, 2026 | Buy | $68.48 | 131,425 | $8,999,984.00 | 459,010 | |
| BJERKHOLT ERIC | MIRM | CHIEF FINANCIAL OFFICER | Jan 22, 2026 | Sell | $93.33 | 1,421 | $132,615.11 | 43,741 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Jan 22, 2026 | Sell | $93.33 | 2,382 | $222,300.63 | 20,655 |
Latest Mirum Pharmaceuticals Inc. News
MIRM Breaking Stock News: Dive into MIRM Ticker-Specific Updates for Smart Investing
PR Newswire
Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Mirum Pharmaceuticals' Tablet Formulation of its Cholestasic Pruritus Treatment Livmarli Approved in Canada
➖
AI Sentiment
Neutral
5/10
Business Wire
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
📈
AI Sentiment
Highly Positive
9/10
Compare MIRM vs Leading Stocks
See how MIRM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MIRM Mirum Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.